Coronavirus: IPRC Updates
COVID-19, the disease caused by coronavirus, has spread fast, locally and globally, threatening health and ways of living across nations. Impacts are felt in politics, economics, public health and social interactions.
The Inequality and Policy Research Center (IPRC) is uniquely positioned to engage intersections of this historic event due to our location within the epicenter of Los Angeles/West Coast and the university’s vantage point facing the Pacific.
IPRC aggregates content from government and leading institutions engaged in the global effort to curtail the coronavirus pandemic. The Center delivers original content from Claremont Graduate University researchers and creates graphic content in GIS modeling.
Contributors: Claudia Caceres, MS; Giacomo Di Pasquale, MA; Nicole Gatto, PhD; Javier Rodriguez, PhD, and Rena Salayeva, PhD. For more, contact Rena Salayeva at firstname.lastname@example.org
Latest Update October 19, 2020, 09.00 a.m.
Click here for previous updates.
For live updates on COVID-19 at the state level, county level and the Claremont neighborhood, you can check our new COVID-19 Claremont Graduate University Dashboard.
- Global: Total confirmed cases: 40,122,835. Total deaths: 1,114,857. Total recoveries: 27,536,738.
- United States: Total confirmed cases: 8,157,704. Total deaths: 219,706. Total recoveries: 3,234,138.
- California: Total confirmed cases: 867,317. Total deaths: 16,943.
- Virus transmission in Los Angeles County is rated as widespread by the governor’s reopening regime, which places LA county in Tier 1 and keeps higher education and K-12 schools closed. Schools are permitted to open to stable groups of no more than 12 students with disabilities, students requiring instruction for English as a second language and students needing other specialized in-school services. Many businesses and services are allowed to reopen if performed outdoors with modifications. (Los Angeles Times)
- Los Angeles County is still in the strictest level of the state’s four-tier economic-reopening roadmap. The county’s recent testing positivity rate is low enough to qualify the county to move up to a less-restrictive tier, but the average daily number of new cases needs to drop to about 700 per day before any movement will occur. (NBC)
Table 1. County-level confirmed cases, deaths, and case-fatality rates.
|County||Confirmed Cases||Deaths||Case-fatality rate per 1,000||Total Population|
Case-fatality rates may be biased due to undercounts in both cases and deaths
- Total of 287222 cases across LA County, including 6855 deaths.
- For the previous 24 hours, 21 new deaths and 1039 new cases.
Cities in Claremont’s neighborhood
Total number of cases: 12932
Table 2. Confirmed cases in Claremont and neighboring cities
|City||Total Confirmed Cases||Total Population|
- With the first coronavirus vaccines in the final stages of testing, the bi-partisan National Governors Association is questioning financing and distribution of vaccines among states. It remains unclear whether vaccines will be allocated based on state total population, or according to the number of people at the highest risk of infection, or by some other rubric. (New York Times)
- Colleges are recording a national enrollment drop during the COVID-19 pandemic. First-year students declined 16.1 percent, accounting for 69 percent of all enrollment losses at the undergraduate level nationally. Community colleges are showing the greatest losses (9.4 percent), while graduate enrollment grew far more than in the previous fall, with the largest gain in public four-year colleges (4 percent). (National Student Clearinghouse Research Center)
- The first round of global COVID-19 vaccinations likely will go to frontline workers, health care professionals and older people. Healthy young people might not get the coronavirus vaccine until 2022, top officials from the World Health Organization said Wednesday. The United States is working toward having a vaccine for mass availability by spring 2021. (The Hill)
- The Senate will vote on a limited coronavirus stimulus bill this month, Majority Leader Mitch McConnell said Tuesday, as lawmakers stumble in their push to send aid to Americans before the 2020 election. The bill will target relief to American voters, including new funding for Paycheck Protection Program small business loans. Democrats, who blocked a roughly $500 billion Republican plan in the Senate last month, could dismiss the latest GOP proposal as inadequate. (CNBC)
- Most IMF loans to help poor countries through the pandemic recommend adoption of tough austerity measures, according to an Oxfam analysis. The report warns that austerity could worsen poverty and inequality and increase vulnerability to COVID-19.
Latest research news
- Nationally, the percentage of tests positive for SARS-CoV-2 and the percentage of visits to emergency departments or outpatient providers for COVID-like illness and influenza-like illness have increased slightly in the past two weeks. Percent positivity decreased slightly among those 18-49 years but increased among the other age groups. The fatality rate, while declining, remains above the epidemic threshold. (CDC Weekly Surveillance Summary)
- A study by the World Health Organization found that remdesivir, an antiviral widely used to treat COVID-19 hospitalized patients, did not reduce death rates in a multinational trial. Inconsistent treatment protocols conducted in diverse health care systems in various countries might be a factor to consider. (New York Times)
- An observational study of 60 patients in Germany found that previous infections with seasonal coronaviruses might protect against a severe course of the SARS-CoV-2 disease. It was shown that elevated antibody levels for HCoVs OC43 and HKU1 were associated with less need for intensive care therapy. (Martin Dugas et al. medRxiv)
- A clinical trial that is testing an antibody treatment for COVID-19 developed by the drugmaker Eli Lilly has been paused because of a potential safety concern. Eli Lilly is one of several companies pursuing experimental treatments for Covid-19 that use monoclonal antibodies — mass-produced mimics of immune molecules that the human body produces in reaction to the coronavirus. (New York Times)
- Genomic analysis of SARS-CoV-2 in a 25-year-old Nevada man shows coronavirus re-infection with two genetically distinct viral agents. The second infection was symptomatically more severe than the first. (Richard Tillett et al. The Lancet)
- The 60,000-patient clinical trial of Johnson & Johnson’s COVID-19 vaccine has been paused due to an unexplained illness in a study participant. It is not yet known whether the participant received a vaccine study treatment or a placebo. (STAT)